Genomic Vision is a publicly-traded company on the Euronext regulated market in Paris
GENOMIC VISION HOSTS 2nd R&D DAY ON OCTOBER 16th IN PARIS
- The management of the Company will present with partners, customers and scientists the advantages of the molecular combing and its outlooks on the Life Science research market (LSR)
Bagneux (France), October 2, 2017 – Genomic Vision (FR0011799907 – GV), a biotech company specialized in the development of diagnostic tests for the early detection of cancers and genetic diseases, will host a second R&D Day on October 16th, 2017, in Paris (Hôtel Bedford – 17 Rue de l’Arcade, 75008 Paris).
This event dedicated to the investors, the analysts and the press will allow them to deepen their knowledge on the growth perspective of GENOMIC VISION on the Life Sciences Research market especially in the field of the oncology research, the quality control and the large rearrangements analysis of the gene editing and DNA replication.
This second edition of R&D Day led by Fabrice Papillon will bring together several KOL’s and Genomic Vision’s partners to discuss the following topics:
- Molecular combing and DNA replication: a new paradigm in the discovery of new therapeutic targets in oncology;
- Molecular combing: a new innovative tool for the comprehension of the formation mechanism of tumors;
- The large genomic rearrangements study: an essential technological contribution on the therapeutic gene editing;
- CRISPR/CAS9 and other molecular scissors: a technological revolution which needs high sensitivity and unbiased quality control solutions.
Aaron Bensimon, CEO of Genomic Vision, declared: “We are very honored to invite our investors, financial analysts and the press to this second R&D Day. This will allow to highlight our positioning, our achievements and our business opportunities on exciting markets as the gene editing and the need for quality control tools to be developed, but also the DNA replication field and the oncology research market in which Genomic Vision has already rewarded a technological collaboration with AstraZeneca”.
ABOUT GENOMIC VISION
GENOMIC VISION is a company specialized in the development of diagnostic solutions for the early detection of cancers and serious genetic diseases and tools for life sciences research. Through the DNA Molecular Combing, a strong proprietary technology allowing the identification of genetic abnormalities, GENOMIC VISION supports the R&D productivity of pharmaceutical companies, leaders in the diagnostic industry and research labs.
The Company develops a strong portfolio of diagnostic tests (breast and colorectal cancers, myopathies) and analysis tools (DNA replication, biomarkers discovery, gene editing quality control). Based in Bagneux, near Paris, the Company employs approximately 60 people. GENOMIC VISION is a public company listed on compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907). For further information, please visit www.genomicvision.com
Co-fondateur et Président du Directoire
Tél. : +33 1 49 08 07 50
Tel. : +33 1 83 62 34 84
Dušan Orešanský / Emmanuel Huynh
Tel. : +33 1 44 71 94 92
Membre des indices CAC® Mid & Small et CAC® All-Tradable
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business.
Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section in its Document de Reference filed with the French Autorité des Marchés Financiers (AMF) on March 28, 2017, under number R.17-009, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.
This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.